JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ko, M.-C.
Right arrow Articles by Woods, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ko, M.-C.
Right arrow Articles by Woods, J. H.

Vol. 289, Issue 1, 378-385, April 1999

Activation of Peripheral kappa  Opioid Receptors Inhibits Capsaicin-Induced Thermal Nociception in Rhesus Monkeys1

Mei-Chuan Ko, Eduardo R. Butelman2 and James H. Woods

Departments of Pharmacology and Psychology, University of Michigan, Ann Arbor, Michigan


    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

8-Methyl-N-vanillyl-6-nonenamide (capsaicin) was locally applied in the tail of rhesus monkeys to evoke a nociceptive response, thermal allodynia, which was manifested as reduced tail-withdrawal latencies in normally innocuous 46°C water. Coadministration of three kappa opioid ligands, U50,488 (3.2-100 µg), bremazocine (0.1-3.2 µg), and dynorphin A(1-13) (3.2-100 µg), with capsaicin in the tail dose-dependently inhibited capsaicin-induced allodynia. This local antinociception was antagonized by a small dose of an opioid antagonist, quadazocine; (0.32 mg), applied in the tail; however, this dose of quadazocine injected s.c. in the back did not antagonize local U50,488. Comparing the relative potency of either agonist or antagonist after local and systemic administration confirmed that the site of action of locally applied kappa opioid agonists is in the tail. In addition, local nor-binaltorphimine (0.32 mg) and oxilorphan (0.1-10 µg) antagonist studies raised the possibility of kappa opioid receptor subtypes in the periphery, which indicated that U50,488 produced local antinociception by acting on kappa 1 receptors, but bremazocine acted probably on non-kappa 1 receptors. These results provide functional evidence that activation of peripheral kappa  opioid receptors can diminish capsaicin-induced allodynia in primates. This experimental pain model is a useful tool for evaluating peripherally antinociceptive actions of kappa agonists without central side effects and suggests new approaches for opioid pain management.


    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

There is a growing literature concerning the antinociceptive effectiveness of exogenous opioids administered in the periphery (for reviews, see Barber and Gottschlich, 1992; Stein 1995). In particular, locally administered opioid agonists produced antinociceptive effects by interacting with peripheral opioid receptors in inflamed tissues (e.g., Stein et al., 1989; Nagasaka et al., 1996; Wilson et al., 1996). Such receptors are present on peripheral sensory nerves where they can modulate both afferent and efferent neuronal functions to eventually result in antinociception (Carlton and Coggeshall, 1998). The discovery that modulation of nociceptive processes can occur in the periphery has stimulated research toward treatments that minimize central side effects. One possibility is the application of small, systemically inactive doses of analgesics directly into the injured tissue (Stein et al., 1991; Joshi et al., 1993). This may be useful, particularly under localized pathologic conditions. Another approach is the use of peripherally selective compounds, which have a reduced ability to cross the blood-brain barrier (Junien and Riviere, 1995; Read et al., 1997). This provides the possibility of systemic administration and may be beneficial in painful conditions of a more dispersed origin. Many nociceptive conditions, including postoperative pain, cancer, and arthritis, are associated with inflammation. In establishing experimental pain models, it is valuable to explore potential antinociceptive agents and to investigate the mechanisms underlying various forms of inflammatory pain.

Capsaicin, the pungent ingredient in hot chili peppers, has been used to evoke nociceptive responses for evaluating antinociceptive agents in humans (Eisenach et al., 1997; Kinnman et al., 1997). Exposure of nociceptor terminals, such as C-fibers, to capsaicin initially leads to excitation of the neuron and, subsequently, to the painful perception and local release of inflammatory pain mediators such as Substance P and calcitonin gene-related peptide (CGRP; e.g., Holzer, 1991; Winter et al., 1995; Caterina et al., 1997). Capsaicin-sensitive nerve fibers play an important role in many types of nociceptive conditions, including arthritis and neuropathic pain (Barthó et al., 1990; Kim et al., 1995; Winter et al., 1995). It has been reported that topical or intradermal administration of capsaicin to human skin produces burning pain and allodynia/hyperalgesia responses (Simone et al., 1989; LaMotte et al., 1992). Previously, we have characterized capsaicin-induced nociception in nonhuman primates (Ko et al., 1998b). After capsaicin was s.c. administered in the tail of rhesus monkeys, it dose-dependently produced thermal allodynia, which was manifested as reduced tail-withdrawal latencies in normally innocuous warm water. More interestingly, when small, systemically inactive doses of µ opioid agonists were coadministered with capsaicin in the tail, they locally inhibited nociceptive responses. These findings support the feasibility of pharmacological studies of capsaicin-induced pain to investigate the function of peripheral opioid receptors (Eisenach et al., 1997; Kinnman et al., 1997).

kappa opioid agonists are of particular clinical interest because of their ability to modulate antinociceptive functions without µ opioid-related side effects, which include constipation, pruritus, and respiratory depression. However, the centrally mediated effects of kappa  agonists, such as sedation and dysphoria, could also limit their usefulness (Pfeiffer et al., 1986; Walsh et al., 1998). Thus, it will be valuable to evaluate peripheral antinociception caused by kappa  agonists in different experimental pain models. To date, many studies indicate that activation of peripheral kappa  receptors contribute to relief of visceral pain (e.g., Junien and Riviere, 1995; Langlois et al., 1997; Burton and Gebhart, 1998). Although rodent studies have also investigated the functional ability of peripheral kappa  receptors against somatic pain (Stein et al., 1989; Nagasaka et al., 1996; Wilson et al., 1996), there are no primate studies exploring this possibility. Given the evidence that peripheral kappa  receptors may act on primary afferents to inhibit nociceptive transmission by C-fibers (Russell et al., 1987; Haley et al., 1990; Andreev et al., 1994), it is possible that activation of peripheral kappa  receptors may inhibit capsaicin-induced nociception in primates. In addition, the possibility of kappa  receptor subtypes has been raised. Based on pharmacological studies, antinociceptive effects of systemic kappa  agonists have been suggested to be mediated by kappa  receptor subtypes (e.g., Horan et al., 1991; Butelman et al., 1993, 1998; Ko et al., 1998a). It is interesting to further explore whether these kappa  agonists produce local antinociceptive effects through different receptor subtypes in the periphery.

Therefore, the aim of this study was to evaluate the hypothesis that local administration of kappa  opioid agonists can diminish capsaicin-induced nociception in rhesus monkeys. The antinociceptive effects of three kappa  ligands, U50,488, bremazocine, and dynorphin A(1-13) [DYN A(1-13)], were compared after local and systemic administration. In addition, further antagonism studies were performed to investigate the possible role of peripheral kappa  receptor subtypes in this procedure.

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Subjects. Six male and female adult rhesus monkeys (Macaca mulatta) with body weights ranging between 7.6 and 11.9 kg (their mean weight during this study was 9.7 kg) were used. They were housed individually with free access to water and were fed approximately 25 to 30 biscuits (Purina Monkey Chow; Ralston Purina Co., St. Louis, MO ) and fresh fruit daily. All monkeys had previous experience in the tail-withdrawal procedure and did not have exposure to capsaicin and opioids for 1 month before the present study. Animals used in this study were maintained in accordance with the University Committee on the Use and Care of Animals in the University of Michigan, and the Guide for the Care and Use of Laboratory Animals (7th ed) by the Institute of Laboratory Animal Resources (Natl Acad Press, Washington D.C., revised 1996).

Procedure. Thermal antinociception was measured by a warm-water tail-withdrawal procedure that has been described previously (Ko et al., 1998b). Briefly, the subjects were seated in restraint chairs and the lower part of the shaved tail (approximately 15 cm) was immersed into warm water maintained at temperatures of 42, 46, and 50°C. Tail-withdrawal latencies were recorded manually on a computerized timer. A maximum cutoff latency (20 s) was recorded if the subjects failed to remove their tails by this time. Each experimental session began with control determinations at each temperature. Subsequent tail-withdrawal latencies were determined at 5, 15, 30, 45, and 60 min after injection. The subjects were tested one to two times at three temperatures in a varying order, with approximately 1- to 2-min intervals between tests. In most cases, experimental sessions were conducted once per week, except in the time course study of nor-binaltorphimine (nor-BNI) antagonism. A single dosing procedure was used in all test sessions.

Experimental Design. Capsaicin was injected s.c. in the terminal 1 to 4 cm of the tail, in a constant 0.1-ml volume. In this procedure, the small amount of capsaicin dose-dependently produced transient allodynia (5-30 min; Ko et al., 1998b). Based on this former characterization, 0.1 mg of capsaicin was chosen as a standard noxious stimulus for the present studies in 46°C water.

Antinociceptive Effects of kappa Agonists. U50,488 (3.2-100 µg), bremazocine (0.1-3.2 µg), or DYN A(1-13) (3.2-100 µg) was coadministered with capsaicin in the tail to assess local antinociceptive effects in 46°C water. Maximally effective local doses of the three agonists were also administered either in the back against capsaicin or in the tail against 50°C water in the absence of capsaicin. In addition, systemic antinociceptive effects of U50,488 (0.032-0.32 mg/kg) and DYN A(1-13) (0.1-3.2 mg/kg) were studied by s.c. administration in the midscapular region of the back immediately after capsaicin injection. As described below (see Data Analysis), comparisons were drawn between potency (ED50 values) of locally administered agents and potency of the same agent administered systemically based on the weight of each animal.

Antagonism of kappa Agonist-Induced Antinociception. Given that onset and distribution factors may be minimized with local administration, opioid antagonists were coadministered with capsaicin and the kappa  agonists in the tail to investigate local antagonist effects. In addition, the highest effective doses of different antagonists were injected s.c. in the back to verify whether the antagonist effects were localized in the tail.

There were three substudies in this experiment. First, quadazocine (0.01-0.32 mg) was coadministered with capsaicin and U50,488 (100 µg) in the tail to evaluate local antagonist potency. Then, quadazocine (0.032-1 mg/kg) was given s.c. in the back 30 min before local injection of capsaicin and U50,488, to determine systemic antagonist potencies. Thus, the relative potency of quadazocine was compared by its ID50 values obtained following local and systemic routes.

Second, nor-BNI, a kappa  antagonist, was administered to determine whether it displayed differential antagonism against the local effects of U50,488 (100 µg) and bremazocine (3.2 µg) in the tail. The dose of nor-BNI (0.32 mg) was initially chosen based on an approximately 100-fold potency difference relative to systemically effective doses in antinociceptive studies in rhesus monkeys (e.g., Butelman et al., 1993). We previously found that systemically administered nor-BNI (3.2 mg/kg) produced inconsistent antinociceptive effects during the first hour after injection. In addition, nor-BNI does not have a clear kappa  selectivity during the first hour after injection (Endoh et al., 1992). To avoid the possible interference of early action of nor-BNI, we used a paradigm similar to one used in a previous study (Butelman et al., 1993). Thus, the data were obtained from separate experiments, in which nor-BNI was initially administered s.c. in the marked tail on day 0. After the nor-BNI injection, the tail-withdrawal responses were measured for 1 h. Then, the local antinociceptive effect of U50,488 or bremazocine against capsaicin was determined 1, 3, 7, 14, and 21 days after local nor-BNI administration by injecting in the marked location. The interval between two experimental sessions was at least 2 weeks. Multiple doses of nor-BNI antagonist were not given because frequent capsaicin exposure in the first week after nor-BNI pretreatment might desensitize the subject's nociceptive responses (Holzer, 1991).

Finally, oxilorphan was chosen to further evaluate the possibility of kappa  receptor subtypes in the periphery. Based on in vivo pA2 analysis, oxilorphan displayed a kappa 1 antagonist selectivity, approximately 7- to 10-fold, in antinociception (M.-C.K., M. D. Johnson, D. W. Tyson, J. R. Traynor and J.H.W., in preparation). Oxilorphan (0.1-10 µg) was coadministered with capsaicin and U50,488 (100 µg) or bremazocine (3.2 µg) in the tail to determine local antagonist potency. The differential potency of oxilorphan was compared with that of quadazocine, based on their local ID50 values.

There were two groups of subjects in this study. The first group (n = 3) was used in all experimental sessions. The second group (n = 3) was used to confirm selected experimental data from the first group; in particular, studies of the time course of local nor-BNI antagonism, locally and systemically effective doses of kappa  agonists against capsaicin, and locally effective doses of antagonists (e.g., quadazocine and oxilorphan) were replicated.

Data Analysis. The 15-min time point was used for analysis because this was the time of peak effects of both capsaicin and kappa  agonists (Ko et al., 1998b). Individual tail-withdrawal latencies were converted to percentage of maximum possible effect (% MPE) by the formula: % MPE = [(test latency - control latency)/(cutoff latency, 20 s - control latency)] × 100. Individual control latencies were averaged from two determinations after application of 0.1 mg of capsaicin in the tail in 46°C water. Mean ED50 values were obtained after log transformation of individual ED50 values, which were calculated by least-squares regression using the portion of the dose-effect curves spanning the 50% MPE, and 95% CL values were also determined. Mean ID50 values of antagonists were determined in the same manner by defining the dose that inhibited the 50% MPE induced by local kappa  agonists. Comparison of relative potencies of each compound administered locally or systemically was performed by converting the mg/kg units to total mg units based on the individual monkey's body weight (i.e., 0.1 mg/kg corresponds to 1 mg, assuming an approximate monkey weight of 10 kg). A significant difference was defined as a lack of overlap in the 95% CL of ED50 or ID50 values. In addition, the dose-dependent effects were analyzed with one-way ANOVA followed by the Newman-Keuls test (p < .01). In the nor-BNI antagonism study, a significant reduction in tail-withdrawal latency was also determined by the Newman-Keuls test (p < .01).

Drugs. U50,488 (Upjohn Co., Kalamazoo, MI), bremazocine methanesulfonate (Sandoz, Basel, Switzerland), DYN A(1-13) (National Institute on Drug Abuse, Bethesda, MD), quadazocine methanesulfonate (Sanofi, Malvern, PA), nor-BNI (obtained from Dr. H. I. Mosberg, Dept. of Medicinal Chemistry, University of Michigan), and oxilorphan tartrate (Bristol Myers Co., Wallingford, CT) were dissolved in sterile water. For systemic administration, all compounds were administered s.c. in the back, at a volume of 0.1 ml/kg. Capsaicin (Sigma Chemical Co., St. Louis, Mo) was dissolved in a solution of Tween 80/ethanol/saline in a ratio of 1:1:8. For local coadministration, all compounds were mixed in capsaicin solution and injected in a 0.1-ml volume in the tail.

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Nociceptive Effects of Capsaicin. Normally, the monkeys kept their tails in 42 and 46°C water until the cutoff time (20 s), which indicated that both temperatures were innocuous. In contrast, they would remove their tails from 50°C water rapidly, typically within 1 to 3 s. When 0.1 mg of capsaicin was injected into the tail, it evoked a nociceptive response, thermal allodynia, which was shown as reduced tail-withdrawal latencies. In particular, from 5 min after injection, capsaicin caused rapid tail-withdrawal latencies of approximately 2 s in 46°C water and this effect lasted for 30 min (Ko et al., 1998b). In the current study, administration of capsaicin caused erythema (redness) at the site of injection in only one monkey. This erythema could not be observed in all subjects due to dark pigmentation of the tail. Thus, a nociceptive response (reduced tail-withdrawal latencies) was used to examine the local effects of kappa  opioids in this preparation.

Antinociceptive Effects of kappa Agonists. Figure 1 compares the local antinociceptive effects of three kappa  agonists, U50,488, bremazocine, and DYN A(1-13). Coadministration of U50,488 (3.2-100 µg) with capsaicin (0.1 mg) in the tail dose-dependently inhibited capsaicin-induced thermal allodynia in 46°C water (Fig. 1, top). However, when applied in the back, the high dose of U50,488 (100 µg) was not effective against capsaicin and it was not locally effective against a noxious stimulus, 50°C water, in the absence of capsaicin. Although the 15-min time point was used to analyze the data, it was worth noting that this ineffectiveness was observed throughout 1 h in the test session. Local administration of bremazocine (0.1-3.2 µg) and DYN A(1-13) (3.2-100 µg) also dose-dependently inhibited capsaicin-induced allodynia (Fig. 1, middle and bottom). Similarly, the antinociceptive effect of bremazocine and DYN A(1-13) was not observed when the high dose of bremazocine (3.2 µg) or DYN A(1-13) (100 µg) was applied in the back or when injected into the tail in 50°C water in the absence of capsaicin. The order of local antinociceptive potency (ED50) was bremazocine (1.0 µg) > U50,488 (26.2 µg) >=  DYN A(1-13) (27.9 µg). As noted, the locally effective doses of these three kappa  agonists did not cause any behavioral changes, such as sedation, after injection.


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 1.   Local antinociceptive effects of U50,488 (top), bremazocine (middle), and DYN A(1-13) (bottom) administered in the tail (slashed columns) or in the back (solid columns) against 46°C water in the presence of capsaicin (0.1 mg) or 50°C water in the absence of capsaicin. Each value represents the mean ± S.E.M. (n = 3-6). Asterisks represent a significant difference (**p < .01; *p < .05) from control. Abscissae, agonist doses in µg. Ordinates, percentage of maximum possible effect (% MPE). Each data point was obtained 15 min after injection. See Materials and Methods for other details.

Figure 2 illustrates the systemic antinociceptive effects of U50,488 and DYN A(1-13). After s.c. administration in the back, U50,488 (0.032-0.32 mg/kg) dose-dependently inhibited capsaicin-induced allodynia. Comparing the potency of both administration routes, local injection of U50,488 was approximately 70-fold more potent than systemic injection (Table 1). In contrast, s.c. administration of DYN A(1-13) (0.1-3.2 mg/kg) did not inhibit capsaicin-induced allodynia. This ineffectiveness was observed through the whole test session (5-60 min). Given that the mean weight of the monkeys was 9.7 kg during this study, 3.2 mg/kg DYN A(1-13) approximately corresponded to a 31-mg total dose per monkey. Thus, the antinociceptive potency of local DYN A(1-13) (ED50 = 27.9 µg) was at least 1000-fold higher than s.c. DYN A(1-13) (Table 1).


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 2.   Systemic antinociceptive effects of U50,488 (top) and DYN A(1-13) (bottom) administered s.c. in the back against capsaicin in 46°C water. Other details are as in Fig. 1.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1
Comparison of potencies of kappa  opioid agonists after local and systemic administration

Antagonism of kappa Agonist-Induced Antinociception. Local administration of quadazocine (0.01-0.32 mg) antagonized the local antinociceptive effects of U50,488 (100 µg) against capsaicin in a dose-dependent manner (ID50, 0.028 mg; 95% CL, 0.017-0.044 mg; Fig. 3, top). When the locally effective dose of quadazocine (0.32 mg) was applied in the back, it did not antagonize local U50,488. This locally effective dose of quadazocine also significantly antagonized local bremazocine (3.2 µg) and DYN A(1-13) (100 µg; data not shown). Although systemic administration of quadazocine (0.032-1 mg/kg) dose-dependently antagonized local U50,488 (ID50, 0.27 mg/kg; 95% CL, 0.11-0.64 mg/kg; Fig. 3, bottom), the relative antagonist potency of quadazocine was approximately 100-fold higher after local versus systemic injections.


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 3.   Antagonist effects of quadazocine administered locally in the tail and systemically in the back against local U50,488 in 46°C water in the presence of capsaicin. The label cap + U50 represents the effects of coadministration of 0.1 mg of capsaicin and 100 µg of U50,488 in the tail. Other details are as in Fig. 1.

Figure 4 illustrates the time course of local antagonist effects of nor-BNI (0.32 mg) against U50,488 and bremazocine. After s.c. injection of nor-BNI in the tail, there were no reduced or elevated tail-withdrawal latencies in 46 and 50°C water, respectively (data not shown). nor-BNI also did not change the monkeys' pain threshold from 24 h and beyond. This local nor-BNI pretreatment produced a significant antagonism against local U50,488 and the antagonist effect was observed up to 1 week after administration. The effects of local U50,488 then returned to control levels by 2 weeks after nor-BNI administration. In contrast, there were no significant antagonist effects of nor-BNI against local bremazocine through all test days (i.e., days 1-21) after nor-BNI pretreatment. In the same pretreatment paradigm, after 0.32 mg of nor-BNI was administered s.c. in the back, it did not antagonize local U50,488 one day after pretreatment (data not shown). The following time course experiment was not continued because we did not want to expose the subjects to frequent capsaicin administration to avoid possible desensitization (Holzer, 1991; Winter et al., 1995).


View larger version (58K):
[in this window]
[in a new window]
  		Fig. 4.   Time course of antagonist effects of nor-BNI (0.32 mg) administered locally in the tail against local U50,488 (top) and bremazocine (bottom) in 46°C water in the presence of capsaicin. Asterisks represent a significant difference (p < .01) from cap + U50. The label cap + brem represents the effects of coadministration of 0.1 mg of capsaicin and 3.2 µg of bremazocine in the tail. Other details are as in Fig. 3.

When oxilorphan was coadministered with capsaicin and U50,488 or bremazocine in the tail, it dose-dependently antagonized local antinociception of both kappa  agonists (Fig. 5). However, oxilorphan displayed a different antagonist potency against U50,488 and bremazocine in that it was approximately 7-fold more potent in antagonizing local U50,488 than bremazocine (Table 2). Similar to nor-BNI, the high dose of oxilorphan (10 µg) alone did not change the monkey's nociceptive responses in this procedure (data not shown). However, quadazocine (0.01-0.32 mg) was coadministered with capsaicin and bremazocine in the tail. It also dose-dependently antagonized local bremazocine, although there was no significant differentiation in the antagonist potency of local quadazocine against U50,488 and bremazocine (Table 2).


View larger version (42K):
[in this window]
[in a new window]
  		Fig. 5.   Local antagonist effects of oxilorphan against local U50,488 (top) and bremazocine (bottom) in 46°C water in the presence of capsaicin. The labels cap + U50 and cap + brem represent the effects of coadministration of capsaicin (0.1 mg) with U50,488 (100 µg) and bremazocine (3.2 µg) in the tail, respectively. Other details are as in Fig. 1.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2
Comparison of potencies of opioid antagonists administered locally in the tail against U50,488 and bremazocine

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The present study illustrated that local administration of kappa  opioid agonists significantly diminished capsaicin-induced nociception in a dose-dependent manner. The antagonist study confirmed that this local antinociception was in the tail and could be mediated by kappa  opioid receptor subtypes. These results support the hypothesis that activation of peripheral kappa  opioid receptors can relieve nociception caused by capsaicin, which is thought to be mediated by stimulating primary afferent C-fibers (Holzer, 1991; Winter et al., 1995; Caterina et al., 1997).

Antinociceptive Effects of kappa Agonists. This is the first demonstration that local administration of selective kappa  agonists U50,488, bremazocine, and DYN A(1-13) can inhibit capsaicin-induced thermal allodynia in nonhuman primates. The locally effective doses of three kappa  agonists, when applied in the back, did not inhibit capsaicin-induced allodynia. This indicates that the site of kappa  agonist-induced antinociception against capsaicin may be located in the tail. In particular, comparing the antinociceptive potency of U50,488 and DYN A(1-13) after local and systemic administration, DYN A(1-13), a kappa  opioid peptide, displayed a large difference in relative potency. Coadministration of DYN A(1-13) with capsaicin in the tail was at least 1000-fold more potent than s.c. administration of DYN A(1-13) in the back. At a dose up to 3.2 mg/kg, DYN A(1-13) did not produce any overt behavioral changes. In contrast, although 0.32 mg/kg U50,488 produced antinociception, this systemic dose also induced a moderate sedation in monkeys (Dykstra et al., 1987; the present study). This observation strengthens the notion that peripheral antinociception can be achieved by local administration of compounds into the injured tissue without producing central side effects (Barber and Gottschlich, 1992; Stein 1995; Wilson et al., 1996).

When a noxious thermal stimulus, 50°C water, was assessed in the absence of capsaicin, local application of kappa  agonists did not produce antinociception. These observations were similar to findings in rodents, in which the antinociceptive potency of opioid agonists is enhanced on the peripheral terminals of nociceptive primary afferents innervating inflamed tissue (Stein et al., 1989; Andreev et al., 1994; Nagasaka et al., 1996). There are several factors that may account for the increased effectiveness of locally administered opioids in a variety of nociceptive origins. For instance, opioid agonists may have easier access to neuronal opioid receptors due to perineurial disruption (Antonijevic et al., 1995). The activity of peripheral sensory fibers is dynamically regulated by the products of tissue injury and inflammation, as well as by a number of exogenous irritant chemicals (Levine et al., 1993; Dray 1997; Carlton and Coggeshall, 1998). The observation that local administration of kappa  agonists is more effective in inflamed tissue could, therefore, have therapeutic value, considering that many painful conditions are associated with tissue injury and inflammation.

Capsaicin evokes pain sensations by activating C-fiber nociceptors and stimulating the release of neuropeptides such as Substance P and CGRP from primary nociceptive afferents (Holzer 1991; Winter et al., 1995; Caterina et al., 1997; Kilo et al., 1997). Both Substance P and CGRP play an important role in neurogenic inflammation and contribute to the transmission of nociceptive information (McDonald et al., 1996; Kilo et al., 1997; Cao et al., 1998). It will be interesting to investigate whether Substance P or CGRP antagonists can relieve capsaicin-induced nociception in this procedure. In contrast, activation of peripheral kappa  receptors has been shown to inhibit the excitability of nociceptive neurons (Russell et al., 1987; Haley et al., 1990; Andreev et al., 1994) and to reduce the release of Substance P from peripheral sensory endings (Yonehara et al., 1992). In addition, in vitro evidence also supports the inhibitory effects of kappa  opioid receptors (e.g., Levine et al., 1993; Schafer et al., 1994; Minami et al., 1995). Capsaicin-sensitive nerve fibers are involved in a variety of nociceptive conditions (Barthó et al., 1990; Kim et al., 1995; Winter et al., 1995). Given the observation that activation of peripheral kappa  receptors can produce antinociception in different experimental pain models (Stein et al., 1989; Nagasaka et al., 1996; Wilson et al., 1996; the present study), clinical studies should explore the possibility of local administration of kappa  opioids for painful conditions with various inflammatory components.

Antagonism of kappa Agonist-Induced Antinociception. Local administration of quadazocine, an opioid antagonist, dose-dependently antagonized the local inhibition of U50,488 against capsaicin-induced allodynia. However, the locally effective dose of quadazocine, when applied in the back, did not antagonize local U50,488. This observation confirms the local agonist study, indicating that the site of action of locally applied kappa  opioids is in the tail. Similarly, a greater relative potency of quadazocine after local versus systemic routes was observed. Compared with a previous study (Ko et al., 1998b), quadazocine is approximately 7-fold more potent in antagonizing fentanyl than U50,488. This different antagonist potency of quadazocine against µ versus kappa  agonists is expected because quadazocine has a higher affinity for µ receptors than kappa  receptors in binding preparations (Negus et al., 1993). Quadazocine has been used previously to differentiate µ receptor- and kappa  receptor-mediated effects in vivo (e.g., Negus et al., 1993).

kappa selective actions of locally applied kappa  agonists were further investigated. The local nor-BNI antagonist study raised the possibility of kappa  receptor subtypes in the periphery. As previously demonstrated by nor-BNI and naltrexone antagonist studies, systemic U50,488 and bremazocine produced antinociception probably through kappa 1 and non-kappa 1 receptors, respectively, in rhesus monkeys (Butelman et al., 1993, 1998; Ko et al., 1998a). In the present preparation, lack of antagonism by nor-BNI against local bremazocine is consistent with results of a previous study using systemic administration of nor-BNI in this species (Butelman et al., 1993). Local nor-BNI displayed a shorter duration of antagonism against local U50,488. This could be due to the site of action (i.e., central versus peripheral) or the smaller local dose that was applied. A larger dose of nor-BNI, applied locally in the tail, could therefore have a longer duration of antagonism against U50,488.

In addition to the nor-BNI antagonist study, oxilorphan was used to evaluate the possibility of kappa 1 opioid receptor subtypes. Similar to naltrexone in vivo pA2 analysis (Ko et al., 1998a), oxilorphan has a 7- to 10-fold selectivity for kappa 1 over non-kappa 1 effects (Ko, 1998). In the present study, local administration of oxilorphan significantly differentiated U50,488- and bremazocine-induced antinociception. In contrast, local quadazocine displayed similar antagonist potency against both kappa  agonists. These results suggested that U50,488 produced local antinociception by acting on kappa 1 receptors, but bremazocine might produce local antinociception on non-kappa 1 receptors. Although bremazocine displayed a high affinity for µ receptor sites, it is unlikely that bremazocine produced antinociception mainly through µ opioid receptors in rhesus monkeys. This can be explained by two functional observations. One is that systemic bremazocine-induced antinociception was not influenced by clocinnamox, a functionally irreversible µ antagonist (Ko et al., 1998a). The other finding is that quadazocine displayed similar potency against U50,488 and bremazocine, but it was more potent in antagonizing µ agonists, such as fentanyl and [D-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin, in this procedure (Ko et al., 1998b). Furthermore, bremazocine has been characterized to be a µ antagonist by in vitro preparations (e.g., Corbett and Kosterlitz, 1986).

Several studies in rodents have suggested that kappa  opioids (kappa 1 versus kappa 2) have distinctive cardiovascular and neurophysiological profiles (Herrero and Headley, 1993; Schoffelmeer et al., 1997). Also, kappa 2 receptors may represent an important route to the modulation of N-methyl-D-aspartate receptor function on certain neuropathologies (Caudle et al., 1994). Other studies have emphasized that kappa  agonists are promising analgesics for treating visceral pain because they are effective on irritable bowel syndrome mainly through peripheral actions, but µ and delta  agonists have direct inhibitory effects on motility and transit, which makes their use deleterious (Junien and Riviere, 1995; Langlois et al., 1997; Read et al., 1997; Burton and Gebhart, 1998). The present study only suggests the functional possibility of kappa  receptor subtypes in the periphery against somatic pain. More studies would be needed to determine whether kappa  subtype agonists have different analgesic efficacy against a variety of pain modalities in primates. To date, due to lack of kappa 2 subtype-selective antagonists and lack of identification of separate clones, there have been difficulties in clarifying the exact nature of proposed kappa  receptor subtypes. The development of kappa  subtype-selective agonists and antagonists would facilitate the pharmacological characterization of these putative receptor subtypes and allow exploration of their potential therapeutic profiles.

In summary, this report demonstrates that local administration of kappa  opioid agonists diminishes capsaicin-induced thermal nociception in nonhuman primates. This experimental pain model could provide a useful tool for evaluating newly developed kappa  agonists and expand new approaches for opioid pain management, such as local administration of kappa  agonists or the use of peripherally selective kappa  agonists.

    Acknowledgments

The authors express their gratitude to Beck McLaughlin for help in preparing the manuscript and Mark Johnson and John Bussenbark for technical assistance.

    Footnotes

Accepted for publication October 30, 1998.

Received for publication August 31, 1998.

1 Support for this research was provided by United States Public Health Services Grant DA00254. Preliminary results were presented at the 60th annual meeting of College on Problems of Drug Dependence, Scottsdale, AZ, June 13-18, 1998.

2 Present address: Rockefeller University, New York, NY

Send reprint requests to: Mei-Chuan Ko, Ph.D., Department of Pharmacology, University of Michigan, 1301 MSRB III, Ann Arbor, MI 48109-0632. E-mail: mko{at}umich.edu

    Abbreviations

Capsaican, 8-methyl-N-vanillyl-6-nonenamide; DYN A(1-13), dynorphin A(1-13); nor-BNI, nor-binaltorphimine; % MPE, percentage of maximum possible effect; CGRP, calcitonin gene-related peptide; U50, 488,(trans)-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide.

    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

0022-3565/99/2891-0378$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
E. R. Butelman, J. W. Ball, T. J. Harris, and M. J. Kreek
Topical Capsaicin-Induced Allodynia in Unanesthetized Primates: Pharmacological Modulation
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1106 - 1114.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. R. Brandt, M. S. Furness, N. K. Mello, K. C. Rice, and S. S. Negus
Antinociceptive Effects of {delta}-Opioid Agonists in Rhesus Monkeys: Effects on Chemically Induced Thermal Hypersensitivity
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 939 - 946.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. C. H. Ko, M. D. Johnson, E. R. Butelman, K. J. Willmont, H. I. Mosberg, and J. H. Woods
Intracisternal Nor-Binaltorphimine Distinguishes Central and Peripheral kappa -Opioid Antinociception in Rhesus Monkeys
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1113 - 1120.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ko, M.-C.
Right arrow Articles by Woods, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ko, M.-C.
Right arrow Articles by Woods, J. H.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition